Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Increase (Decrease) in Derivative Liabilities

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Derivative Liabilities

AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Derivative Liabilities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2026-02-26

  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-12-31 was -$760.00K.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-09-30 was $0.00.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-06-30 was $0.00.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2023-03-31 was $0.00.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2025 was $0.00.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2024 was $0.00.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2023 was -$760.00K.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2022 was -$1.06M.
Period endIncrease (Decrease) in Derivative Liabilities 3 monthIncrease (Decrease) in Derivative Liabilities 6 monthIncrease (Decrease) in Derivative Liabilities 9 monthIncrease (Decrease) in Derivative Liabilities 12 month
2025-12-31$0.00
10-K · filed 2026-02-26
2024-12-31$0.00
10-K · filed 2026-02-26
2023-12-31-$760.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$760.00K
derived: sum of 2 quarters · filed 2026-02-26
-$760.00K
derived: sum of 3 quarters · filed 2026-02-26
-$760.00K
10-K · filed 2026-02-26
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$0.00
derived: sum of 2 quarters · filed 2023-11-08
$0.00
10-Q · filed 2023-11-08
$0.00
derived: sum of 4 quarters · filed 2024-03-14
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28
$0.00
10-Q · filed 2023-08-28
$0.00
derived: sum of 3 quarters · filed 2024-03-14
-$350.00K
derived: sum of 4 quarters · filed 2024-03-14
2023-03-31$0.00
10-Q · filed 2023-05-08
$0.00
derived: sum of 2 quarters · filed 2024-03-14
-$350.00K
derived: sum of 3 quarters · filed 2024-03-14
-$350.00K
derived: sum of 4 quarters · filed 2024-03-14
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$350.00K
derived: sum of 2 quarters · filed 2024-03-14
-$350.00K
derived: sum of 3 quarters · filed 2024-03-14
-$1.06M
10-K · filed 2024-03-14
2022-09-30-$350.00K
10-Q · filed 2022-11-03
-$350.00K
derived: sum of 2 quarters · filed 2022-11-03
-$1.06M
10-Q · filed 2023-11-08
-$1.17M
derived: sum of 4 quarters · filed 2023-08-28
2022-06-30$0.00
10-Q · filed 2022-11-03
-$710.00K
10-Q · filed 2023-08-28
-$820.00K
derived: sum of 3 quarters · filed 2023-08-28
-$820.00K
derived: sum of 4 quarters · filed 2023-08-28
2022-03-31-$710.00K
10-Q · filed 2023-05-08
-$820.00K
derived: sum of 2 quarters · filed 2023-08-28
-$820.00K
derived: sum of 3 quarters · filed 2023-08-28
-$1.39M
derived: sum of 4 quarters · filed 2023-08-28
2021-12-31-$110.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
-$110.00K
derived: sum of 2 quarters · filed 2023-08-28
-$680.00K
derived: sum of 3 quarters · filed 2023-08-28
-$600.00K
10-K/A · filed 2023-08-28
2021-09-30$0.00
10-Q · filed 2021-11-04
-$570.00K
derived: sum of 2 quarters · filed 2021-11-04
-$490.00K
10-Q · filed 2022-11-03
-$544.00K
derived: sum of 4 quarters · filed 2023-08-28
2021-06-30-$570.00K
10-Q · filed 2021-11-04
-$490.00K
10-Q · filed 2022-08-04
-$544.00K
derived: sum of 3 quarters · filed 2023-08-28
-$444.00K
derived: sum of 4 quarters · filed 2023-08-28
2021-03-31$80.00K
10-Q · filed 2022-05-09
$26.00K
derived: sum of 2 quarters · filed 2023-08-28
$126.00K
derived: sum of 3 quarters · filed 2023-08-28
$276.00K
derived: sum of 4 quarters · filed 2023-08-28
2020-12-31-$54.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
$46.00K
derived: sum of 2 quarters · filed 2023-08-28
$196.00K
derived: sum of 3 quarters · filed 2023-08-28
$286.00K
10-K/A · filed 2023-08-28
2020-09-30$100.00K
10-Q · filed 2020-11-05
$250.00K
derived: sum of 2 quarters · filed 2020-11-05
$340.00K
10-Q · filed 2021-11-04
$340.00K
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$150.00K
10-Q · filed 2020-11-05
$240.00K
10-Q · filed 2021-08-05
$240.00K
derived: sum of 3 quarters · filed 2022-03-01
$240.00K
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$90.00K
10-Q · filed 2021-05-10
$90.00K
derived: sum of 2 quarters · filed 2022-03-01
$90.00K
derived: sum of 3 quarters · filed 2022-03-01
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$0.00
derived: sum of 2 quarters · filed 2022-03-01
$0.00
10-K · filed 2022-03-01
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$0.00
10-Q · filed 2020-11-05
2019-06-30$0.00
10-Q · filed 2020-08-10
2018-12-31$0.00
10-K · filed 2021-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33